By Julia Karow
Complete Genomics said in a filing with the Securities and Exchange Commission last week that it has sold $14.49 million in securities.
CEO Cliff Reid told In Sequence by e-mail today that the amount raised in the sale represents "a portion" of the company's Series D financing, which is not yet complete. He declined to provide further details.
According to the "Form D" filing, which the company filed July 2 as an amendment to a prior filing, Complete Genomics has sold $14.49 million in debt, options, warrants, and securities. The filing lists Feb. 13 as the date of first sale.
The document also notes that Complete is not making its securities offering "in connection with a business combination transaction, such as a merger, acquisition, or exchange offer."
The company, which plans to launch a human whole-genome sequencing service for research organizations this summer, revealed in April that it had to implement cost-cutting measures because of a delay in its Series D financing (see In Sequence 4/14/2009).
Last month, Reid said the firm plans to announce news regarding its service and fundraising activities this month (see In Sequence 6/16/2009).